SUMMARY The acute hemodynamic effects of an i.v. bolus of verapamil, 0.1 mg/kg or 0.06-0.075 mg/kg, were examined by serial radionuclide studies in 46 patients with coronary artery disease. In 20 patients with ejection fractions (EFs) > 35% (group 1A), verapamil, 0.1 mg/kg given over 1-1'/2 minutes, had a biphasic effect: first, a transient decrease in EF accompanied by increased left ventricular (LV) volumes and cardiac output equivalents; then, an overshoot of EF to values above control, accompanied by a decrease in peripheral vascular resistance and a drastic decrease in LV volumes, while cardiac output equivalent remained slightly elevated. In eight patients with EFs < 35% (group 1B), only the first effect on EF was noted. In 10 patients with EFs > 35% (group 2), verapamil, 0.0640.075 mg/kg, exerted qualitatively similar but milder effects on hemodynamic function. Finally, verapamil, 0.1 mg/kg given more slowly, over 2-21/2 minutes, produced no significant changes in EF or LV volumes in another eight patients (group 3). The acute effects of verapamil are thus both time-related and dose-dependent. They are also related to the baseline functional reserve of the left ventricle. This study documents that verapamil exerts a depressant effect on LV function. However, the transient nature of this depression and the quick recovery to normal or above-normal values indicate that verapamil, in the doses used in this study, is safe to use intravenously in patients with coronary artery disease.
VERAPAMIL has found ever-increasing uses in cardiology.1-3 The ability of verapamil to inhibit inward calcium flux through the so-called slow channels is believed to be its mechanism of action.3-Initial studies in cardiac muscle preparations and in experimental animals suggested that the calcium-inhibiting properties of verapamil make it an extremely powerful, negative inotropic agent.7' 8 Subsequent studies in man show a wide margin of safety in the use of the drug.9' '0 However, little is known about the effects of i.v. verapamil in patients with coronary artery disease, and fears have been expressed concerning its safety in these patients. We therefore examined the acute hemodynamic effects of an i.v. bolus of verapamil by gated radionuclide ventriculography'-115 in 46 ambulatory patients with coronary artery disease. Specifically, we evaluated the rapid and transient changes in the cardiocirculatory system in the first few minutes after the injection.
Methods Subjects
Forty-one men and five women, ages 39-67 years (mean + SD 56 + 8 years), with angina pectoris secondary to coronary artery disease participated in this study. The diagnosis of coronary artery disease was based on documentation of previous acute myocardial infarction in 39 patients (anterior in 26, inferior in 10 and in both locations in three), followed in all by typical mild-to-moderate angina pectoris. In the seven other patients, the diagnosis of coronary artery disease was established by the presence of typical angina pectoris, brought on by effort and relieved by rest and nitroglycerin. The diagnosis of these seven patients was further documented by positive exercise tests and exercise-induced myocardial perfusion defects on the 201-thallium perfusion study, with a return to normal perfusion on equilibration 4 hours later. Cineangiographic documentation of significant two-or threevessel coronary disease was available in 10 patients. None of the patients had valvular regurgitation. One had associated aortic stenosis and one had undergone valve replacement. Three had documented left ventricular aneurysms. Twenty-eight patients were taking oral nitrates for angina pectoris; three were receiving propranolol for angina or for hypertension. Four patients received digoxin or diuretics for congestive heart failure and three were receiving amiodarone. Digoxin, diuretics and antiarrhythmic drugs were continued through the morning of the test to ensure a stable hemodynamic state before the test. All patients were tested in the postabsorptive state between 2:00 and 4:00 p.m., at least 6 hours after the last dose of oral nitrates, to minimize the degree of vasodilatation.
Testing Procedure All patients gave informed consent and were studied in the nuclear medicine laboratory. An indwelling catheter was placed in an arm vein. The patient was then positioned supine on a comfortable table under the collimator and remained in this resting state for 30 minutes, in order to achieve steady state, as judged by a stable heart rate on the ECG and arm-cuff blood pressure. Care was taken that the patient remained quiet and awake during the entire procedure.
Two baseline studies were performed in the 450 left VOL 67, No 1, JANUARY 1983 anterior oblique (LAO) position. Verapamil was then injected in one i.v. bolus as described below. Acquisitions were then serially obtained every 2 minutes after verapamil over the next 10 minutes. Blood pressure was repeatedly monitored with a sphygmomanometer during each phase of the study and the ECG was continuously recorded during the entire procedure.
Verapamil Injections
Verapamil was administered in a bolus of 0. 1 mg/kg over 1-11/2 minutes to 28 patients (group 1). In another group of 10 patients (group 2), a bolus of 0.06-0.075 mg/kg was administered within the same period of time to evaluate the effect of smaller doses of verapamil. In eight patients (group 3), a bolus of 0.1 mg/kg was injected over 2-21/ minutes. lar time-activity curve is then automatically calculated by the computer by using the second derivative method, with end-diastole represented by the highest number of counts at the early uppermost point in the curve, and end-systole represented by the lowest number of counts at the nadir of the curve.
At the beginning of acquisition, actual time per frame was determined by the computer, and the total number of cycles used for the acquisition of the 3000 kilocounts was registered for each study. Ejection fraction was calculated by the computer from backgroundcorrected end-diastolic and end-systolic counts. To determine left ventricular radionuclide volume equivalents, formula 1 of Slutsky et al. I I was considered to be the simplest and most suitable for the purpose of this study. According to this formula,
Radionuclide Studies
Lyophilized pyrophosphate solution that contained 1. 75 mg of Sn (Sorek NRC) was injected intravenously. Thirty minutes later, a solution of technetium-99m pertechnetate (TcO4, Sorek NRC) was injected through the indwelling catheter in a dose of 30-35 mCi. After distribution of the radionuclide in the blood pool, data were collected up to a preset total of 3000 kilocounts, which usually took 2 minutes to acquire. All studies were performed using a commercial scintillation camera equipped with an all-purpose, medium resolution, medium-sensitivity, collimator (Elscint CE-1 and CCL-3).
The camera was positioned in the 450 left anterior oblique position, which included a 5-10°caudal tilt for maximal isolation of the left ventricle from the right ventricle and left atrium when necessary. The left anterior oblique position was adjusted for optimal visualization of the septum and separation of the left and right ventricles.
The data were acquired using the SYMA (Synchronized Multigated Acquisition) mode, using the R wave of the ECG fed into a minicomputer (Elscint Dykomette). The latter divides the RR interval into equal "frames" (16 for this study), derives the actual time for each frame and sums cardiac cycles at each corresponding frame to assemble a composite cardiac cycle. Each image frame has a spatial resolution of 32 x 32 channel elements (pixels) in the zoom x 2 mode.
The data were stored in a "floppy-diskette" and displayed on a color or black-and-white image display screen for visualization and photographic recording. Time-activity curves for the left ventricle at each stage of the study were generated by using a semiautomated left ventricular edge-detection technique developed by the manufacturer of the system. The operator places an initial region of interest (ROI) around the ventricle as visualized on the image display screen. The system allows frame-by-frame adjustment of the ROI to closely approximate the outline of the left ventricle as its size decreases from end-diastole to end-systole. Subtraction of background activity as contained in the original ROI is automatically performed by the computer. The final, background-corrected, left ventricu-EDC or ESC 0.04 seconds
No. of heart beats actual time/frame where V = volume, EDC = end-diastolic counts, ESC = end-systolic counts, heart beats = the number of cycles required for data acquisition, and actual time/ frame -the time for acquisition of counts during each of the 16 frames.
The value obtained from this and other equations using radionuclide studies does not represent actual volumes in milliliters, but rather, radionuclide "volume equivalents" that are reasonably well correlated with contrast angiographic volumes.'1 Because each patient served as his own control and changes in volumes and ejection fraction from baseline values were studied, the conclusions obtained by this equation are valid for this study.
Hemodynamic Equations
The following equations were used to determine relative changes from baseline in each patient. creased mean heart rate by 9.5% in group 1A and by 5.5% in group lB and decreased systolic and diastolic blood pressure by 7% in group lA and by 10-I 1% in group lB (table 2) . Systemic vascular resistance decreased by 25% in group lA (p < 0.0005) and by 23% in group lB (NS because of the small sample). Verapamil, 0.060-0.075 mg/kg, exerted a similar effect on heart rate, blood pressure and vascular resistance in group 2. Verapamil, 0.1 mg/kg given over 2-2/2 minutes, decreased blood pressure 16% and increased heart rate 13% in group 3. No significant effect was noted on the PR interval.
Immediate Effects of Verapamil on LV Function
In the first radionuclide study performed in group 1 A 2-4 minutes after the beginning of injection, verapamil, 0. 1 Mean end-diastolic and end-systolic left ventricular nuclide volume equivalents were increased by 34% and 60% of their respective baseline values in group LA ( fig. 2 ) and by 28% and 34% respectively in group LB ( fig. 3 ). Nuclide stroke volume equivalent immediately increased by 14% from baseline (NS), cardiac output equivalent by 25%, and stroke work equivalent by 5% in group lA (NS). These changes were smaller in group LB.
Recovery Stage
The effects 4-6 minutes after administration of verapamil differed sharply between groups LA and LB.
Immediately after the initial decline in ventricular function seen in the first 2-4 minutes after the beginning of the injection, ejection fraction not only immediately returned to its baseline value, but it also overshot it and became "supernormal" in group LA (62.7 + 12% vs 55.0 ± l l%; p < 0.0005), with a gradual return to the normal value within the next 6-8 minutes after the beginning of the injection. The maximum ejection fraction thus represents a 14% increase above the control value ( fig. 2 ). This increase in ejection fraction was observed in all 20 a result of both its vasodilating and myocardial depressant activity, which may lead to congestive heart failure. 6 In this study, none of these hazardous effects was observed when verapamil was given in a bolus of 0.1 mg/kg over 1-1 1/2 minutes. This dose is slightly greater than the dose of 5 mg usually given as a single bolus to patients with arrhythmias, and the time of administration is slightly shorter than the usual 2-5 minutes.6 ' 28,30 The fact that this dose was well tolerated by 28 patients, including eight with moderately to extremely reduced ejection fraction, indicates that verapamil is relatively safe for patients with coronary artery disease, even in the presence of compromised ventricular function, despite its depressant properties on the myocardium. Our study thus supports recent reports.23-25. 31 . 32 The safety of verapamil in the doses used here remains to be determined in patients with acute left ventricular dysfunction.
The hemodynamic effects of verapamil in man have been investigated during catheterization.23-25, [31] [32] [33] [34] Conflicting results have been reported, probably because of the varying laboratory conditions, differing subsets of subjects, methods of administration of verapamil and methods of quantitation. Cardiac output has been reported to decrease,35 increase24, 25 34 or not change,9' 10 and stroke volume has been reported either not to change9 or to increase.24' 25 Left ventricular enddiastolic pressure, pulmonary wedge pressure and left atrial pressure have been reported not to change'10 34 or to increase.9 24 25 3 Left ventricular or aortic dP/dt has been reported to decrease'10 25, 33 or not to change,9 while mean velocity of circumferential fiber shortening has been reported to increase24 and ejection fraction not to change10 or to increase.24 Thus, the reported effects of verapamil on hemodynamic indexes of left ventricular function vary from study to study.
Ferlinz et al.23 examined left ventricular dimensions by ventriculography in 20 patients with coronary artery disease. The end-diastolic volume did not change and end-systolic volume decreased (resulting in increased ejection fraction) when examined 20-28 minutes after beginning of a continuous infusion. M-mode echocardiographic end-diastolic and end-systolic dimensions (and, therefore, ejection fraction), however, did not change in five patients with coronary artery disease studied 5 minutes after a bolus of verapamil. Because of technical limitations, ventricular volumes have not previously been examined within the first few minutes of verapamil injection, at a time when the most rapid and dramatic hemodynamic changes in the cardiovascular system can be expected to take place. More recently, Vlietstra et al.34 studied diastolic volumes by left ventriculography during continuous verapamil infusion and found that they increased. 34 Radionuclide techniques have been used to study the acute effects of i.v. verapamil.35 36 In two studies, verapamil was given in a continuous infusion after a bolus injection. In the first study,3 no significant change was noted in pulmonary capillary wedge pressure and ejection fraction at rest, while verapamil prevented the fall in ejection fraction noted during atrial pacing. In the Thus, verapamil in the doses and time of injection used clinically indeed depresses left ventricular function in man, as shown by the increased volumes demonstrated in this study, by increased end-diastolic pressure9 2325 36 and by decreased dP/dt.33 However, this depressant effect is short-lived and evanescent in the heart with reasonably preserved myocardial reserve, and is somewhat more prolonged in the presence of severe left ventricular dysfunction when doses of 0.1 mg/kg are used. In doses of 0.6-0.75 mg/kg, which are even closer to the frequently used standard bolus of 5 mg, or when the larger dose of 0.1 mg/kg is given more slowly, the effects of verapamil are even less pronounced and more short-lived. Also of interest, peripheral vasodilation is still demonstrable after slow injection of verapamil, although the myocardial depression is no longer evident (group 3).
In conclusion, rapid administration of a bolus of verapamil in patients with coronary artery disease is followed by a series of interrelated adjustments that lead to varying hemodynamic results, depending on the underlying cardiovascular state of the particular patient tested. The effects are a combination of marked but transient left ventricular depression and decreased afterload. The most important overall effect of verapamil on the cardiovascular system as an integrated system appears to be an improvement in function, brought about by decreased resistance to ventricular emptying and, perhaps, by a sympathetically mediated increase in myocardial contractility, provided the sympathetic reflex mechanisms are intact. Verapamil is well tolerated in bolus injections, even in severe left ventricular dysfunction in the doses used here. We cannot extrapolate our data to larger doses or to continuous infusions, because cumulative effects may produce different hemodynamic consequences. Similarly, the safety of an i.v. bolus of verapamil in acute left ventricular decompensation must be determined by a similar investigational protocol. SUMMARY The kinetics of accumulation and the external imaging patterns of indium-111-labeled platelets infused in a dog model of left anterior descending coronary artery occlusion with reperfusion were studied. The effects of infarct age and regional residual myocardial blood flow upon platelet accumulation were quantified, and the capacity of indium-111 platelets to image the experimental infarction was evaluated qualitatively. The endocardial accumulation of indium-111 platelets occurred primarily in infarct zones with residual blood flow < 0.6 times normal and was maximal (24.98 ± 2.76 times normal) in the lowest blood flow zone (< 0.1 times normal). Indium-111 platelet accumulation in the epicardium occurred in the regions with blood flow < 0.6 times normal and was maximal (17.83 ± 1.20 times normal) in the lowest blood flow zone (< 0.1 times normal). The maximal endocardial and epicardial platelet accumulation occurred 24 hours after reperfusion and was significantly decreased at 48 hours. In vivo cardiac images revealed discrete areas of increased myocardial radioactivity uptake in the anterior wall of dogs 24 hours after reperfusion. All images 48 hours after reperfusion were negative. Thus, in the experimental setting, indium-111 platelets allow quantification of platelet accumulation after myocardial infarction at a tissue level and provide a noninvasive means of in vivo imaging of reperfused infarcted myocardium.
PLATELET accumulation in areas of myocardial infarction has been demonstrated histologically and with chromium-5 1 (5'Cr)-labeled platelets.1 2 Indium-I ll ("'In)-labeled platelets have been used to identify left ventricular thrombi,3 coronary bypass graft thrombi4 and acute coronary artery thrombi.5 The ability to image the inflammatory response to acute myocardial infarction in dogs and man using "'In-labeled leukocytes has been demonstrated.6'7 Recent studies also suggest the crucial role that platelet aggregate microemboli may play in infarct extension2,8 and fatal ventricular arrhythmias.9 Definition of the kinetics of platelet accumulation into acute infarct zones is important because platelet inhibitors may limit the degree of ischemic necrosis'0 and may prevent fatal ventricular arrhythmias resulting from acute myocardial infarction."I The development of the technique for "I'In labeling of platelets provides a direct means for assess-
